Structural biology approaches to antibacterial drug discovery

Expert Opinion on Drug Discovery

Volumn 2, Issue 8, 2007, Pages 1085-1101

  Hollert, Tod P ^a   Evdokimov, Artem G ^a   Narasimhan, Lakshmi ^a  

^a PFIZER INC   (United States)

Author keywords

Antibacterial agent; Drug target; Eubacteria; Fragment based screening; High throughput screening; Structural genomics; Structure based design

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE 2 INHIBITOR; 3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE 3 INHIBITOR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BAMBERMYCIN; BBT 78484; BL 11B3; CEPHALOSPORIN; CHIR 090; CIPROFLOXACIN; DIHYDROFOLATE REDUCTASE INHIBITOR; ENZYME INHIBITOR; GYRASE INHIBITOR; ICLAPRIM; INDOLINONE; MEMBRANE PROTEIN; MJ 0577; NEAMINE ANALOG 1; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN BINDING PROTEIN; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; PLATENSIMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RX A 8; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE 3 O (3 HYDROXYMYRISTOYL) N ACETYLGLUCOSAMINE DEACETYLASE INHIBITOR; VRT 752586;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG TARGETING; DRUG TOLERANCE; GENE TARGETING; GRAM NEGATIVE INFECTION; HIGH THROUGHPUT SCREENING; HUMAN; INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENOMICS; STRUCTURE ACTIVITY RELATION;

EID: 34548439949     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.8.1085     Document Type: Review

References (99)

1. ALEKSHUN MN, LEVY SB: Commensals upon us. Biochem. Pharmacol. (2006)71:893-900.
2. RICE LB: Unmet medical needs in antibacterial therapy. Biochem. Pharmacol. (2006) 71:991-995.
3. TALBOT GH, BRADLEY J, EDWARDS JE et al.: Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin. Infect. Dis. (2006) 42:657-668.
4. STEIN J: Innovative antibacterial drugs: nothing ventured, nothing gained. Expert Opin. Investig. Drugs (2005) 14(2):107-109.
5. PAYNE DJ, GWYNN MN, HOLMES DJ, POMPLIANO DL: Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. (2007) 6:1-12.
6. SILVER LL: Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. (2007) 6:41-55.
7. OVERBYE KM, BARRETT JF: Antibiotics: where did we go wrong? Drug Discov. Today (2005) 10(1):45-52.
8. LEEDS JA, DEAN CR: Peptide deformylase as an antibacterial target: a critical assessment. Curr. Opin. Pharmacol. (2006) 6:445-452.
9. GENTRY DR, INGRAHAM KA, STANHOPE MJ et al.: Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionly-tRNA synthetase genes. Antimicrob. Agents Chemother. (2003) 47(6):1784-1789.
10. HEATH RJ, ROCK CO: A triclosan-resistant bacterial enzyme. Nature (2000) 406:145.
11. DONADIO S, BRANDI L, SERINA S, SOSIO M, STINCHI S: Discovering novel antibacterial agents by high throughput screening. Front. Drug Des. Disc. (2005) 1:3-16.
12. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (1997) 23:3-25.
13. VISWANADHAN VN, BALAN C, HULME C, CHEETHAM JC, SUN Y: Knowledge-based approaches in the design and selection of compound libraries for drug discovery. Curr. Opin. Drug Disc. Devel. (2002) 5(3):400-406.
14. BLEICHER KH, BOEHM H-J, MUELLER L, ALANINE AI: Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Disc. (2003) 2:369-378.
15. BARKER JJ: Antibacterial drug discovery and structure-based design. Drug Discov. Today (2006) 11(9/10):391-404.
16. SCHMID MB: Crystallizing new approaches for antimicrobial drug discovery. Biochem. Pharmacol. (2006) 71:1048-1056.
17. DALE GE, BROGER C, D'ARCY A et al.: A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance, J. Mol. Biol. (1997) 266:23-30.
18. SORBERA LA, CASTANER J, RABASSEDA X: Iclaprim. Drugs Fut. (2004) 29(3):220-225.
19. HAUSER S, LOCIURO S, ISLAM K: Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. (2006) 71:941-948.
20. YUSUPOV MM, YUSUPOVA GZ, BAUCOM A et al.: Crystal structure of the ribosome at 5.5 Å resolution. Science (2001) 292:883-896.
21. SCHLUENZEN F, TOCIJ A, ZAIRVACH R et al.: Structure of functionally activated small ribosomal subunit at 3.3 A resolution. Cell (2000) 102(5):615-623.
22. WIMBERLY BT, BRODERSEN DE, CLEMMONS WM Jr et al.: Structure of the 30S ribosomal subunit. Nature (2000) 407:615-623.
23. HARMS J, SCHLUENZEN F, ZARIVACH R et al.: High resolution structure of the large ribosomal subunit from a mesophilic eubacterium. Cell (2001) 107(5):679-688.
24. BAN N, NISSEN P, HANSEN J, MOORE PB, STEITZ TA: The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science (2000) 289:905-920.
25. GUYMON R, POMERANTZ SC, ISON JN, CRAIN PF, MCCLOSKEY JA: Post-translational modifications in the small subunit ribosomal RNA from Thermotoga maritima, including presence of a novel modified cytidine. RNA (2007) 13:396-403.
26. RODNINA MV, BERINGER A, WINTERMEYER W: How ribosomes make peptide bonds. Trends Biochem. Sci. (2007) 32(1):20-26.
27. FRANCESCHI F, DUFFY EM: Structure-based drug design meets the ribosome. Biochem. Pharmacol. (2006) 71:1016-1025.
28. MURRAY JB, MEROUEH SO, RUSSELL RJM et al.: Interactions of designer antibiotics and the ribosomal aminoacyl-tRNA site. Chem. Biol. (2006) 13:129-138.
29. MAXWELL A, LAWSON DM: The ATP-binding site of type-II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. (2003) 3:283-303.
30. HOLDGATE GA, TUNNICLIFFE A, WARD WH et al.: The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant gyrase: a thermodynamic and crystallographic study. Biochemistry (1997) 36:9663-9673.
31. BELLON S, PARSONS JD, WEI Y et al.: Crystal structures of Escherichia coli topoisomerase IV par E subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. (2004) 48(5):1856-1864.
32. MANI N, GROSS CH, PARSONS JD et al.: In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob. Agents Chemother. (2006) 50(4):1228-1237.
33. GROSSMANTH, BARTELS DJ, MULLIN S et al.: Dual targeting of GyrB and Par E by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob. Agents Chemother. (2007) 51(2):657-666.
34. WHITE RJ, MARGOLIS PS, TRIAS J, YUAN Z: Targeting metalloenzymes: a strategy that works. Curr. Opin. Pharmacol. (2003) 3(5):502-507.
35. VUORIO R, VAARA M: The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrob. Agents Chemother. (1992) 36:826-829.
36. WHITTINGTON DA, RUSCHE KM, SHIN H, FIERKE CA, CHRISTIANSON DW: Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc. Natl. Acad. Sci. USA (2003) 100(14):8146-8150.
37. COGGINS BE, MCCLERREN AL, JIANG L et al.: Refined solution structure of the LpxC-TU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design. Biochemistry (2005) 44:1114-1126.
38. GENNADIOS HA, WHITTINGTON DA, LI X, FIERKE CA, CHRISTIANSON DW: Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase. Biochemistry (2006) 45:7940-7948.
39. JACKMAN JE, FIERKE CA, TUMEY LN et al.: Antibacterial agents that target lipid A biosynthesis in Gram-negative bacteria. J. Biol. Chem. (2000) 275(15):11002-11009.
40. GENNADIOS HA, CHRISTIANSON DW: Binding of uridine 5′-diphosphate in the "basic parch" of the zinc-dependent deactylase LpxC and implications for substrate binding. Biochemistry (2006) 45:15216-15223.
41. ONISHI HR, PELAK BA, GERKENS LS et al.: Antibacterial agents that inhibit lipid A biosynthesis. Science (1996) 274:980-982.
42. CLEMENTS JM, COIGNARD F, JOHNSON I et al.: Antibacterial activities and characterization of novel inhibitors of Lpx C. Antimicrob. Agents Chemother. (2002) 46(6):1793-1799.
43. KLINE T, ANDERSEN NH, HARWOOD EA et al.: Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC. J. Med. Chem. (2002) 45(14):3112-3129.
44. PIRRUNG MC, TUMEY LN, RAETZ CRH et al.: Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups. J. Med Chem. (2002) 45(19):4359-4370.
45. BARB AW, MCCLERREN AL, SNEHELATHA K et al.: Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry (2007) 46(12):3793-3802.
46. CAMPBELL JW, CRONAN JE: Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. (2001) 55:305-332.
47. DAVIES C, HEATH RJ, WHITE SW, ROCK CO: The 1.8 Å crystal structure and active-site architecture of β-ketoacyl-acyl carrier protein synthase III (FabH) from Escherichia coli. Structure (2000) 8:185-195.
48. QUI X, JANSON CA, SMITH WW et al.: Refined structures of β-ketoacyl-acyl carrier protein synthase III. J. Mol. Biol. (2001) 307:341-356.
49. QIU X, CHOUDHRY AE, JANSON CA et al.: Crystal structure and substrate specificity of the β-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Protein Sci. (2005) 14:2087-2094.
50. MUSAYEV F, SACHDEVA S, SCARSDALE JN, REYNOLDS KA, WRIGHT HT: Crystal structure of a substrate complex of Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A. J. Mol. Biol. (2005) 346:1313-1321.
51. DAINES RA, PENDRAK I, SHAM K et al.: First X-ray co-crystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J. Med Chem. (2003) 46(1):5-8.
52. WANG J, SOISSON SM, YOUNG K et al.: Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature (2006) 441:358-361.
53. NIE Z, PERRETTA C, LU J et al.: Structure-based design, synthesis and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J. Med. Chem. (2005) 48:1596-1609.
54. YOUNG K, JAYASURIYA H, ONDEYKA JG et al.: Discovery of FabF/FabH inhibitors from natural products. Antimicrob. Agents Chemother. (2006) 50(2):519-526.
55. UEMURA N, OKAMATO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. (2001) 345(11):784-789.
56. RUZHEINIKOV SN, TAAL MA, SEDELNIKOVA SE, BAKER PJ, RICE DW: Substrate-induced conformational changes in Bacillus subtilis glutamate racemase and their implications for drug discovery. Structure (2005) 13:1707-1713.
57. FISHER SL, KERN G, NEWTON T et al.: Identification and biochemical characterization of agents selective for Helicobacter pylori glutamate racemase. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005).
58. GOWRAVRAM M, BASARAB G, EYERMANN C et al.: Design and synthesis of potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI) Poster F-1877. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005).
59. YUAN Y, BARRETT D, ZHANG Y et al.: Crystal ctructure of a peptidoglycan glycosyltransferase suggests a model of processive glycan chain synthesis. Proc. Natl. Acad. Sci. USA (2007) 104:5348-5353.
60. LOVERING AL, CASTRO LHD, LIM D, STRYNADKA NCJ: Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science (2007) 315:1402-1405.
61. LOMOVSKAYA O, BOSTIAN KA: Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem. Pharmacol. (2006) 71:910-918.
62. LOMOVSKAYA O, ZGURSKAYA HI, TOTROV M, WATKINS WJ: Waltzing ttansporters and 'the dance macabre' between humans and bacteria. Nat. Rev. Drug Discov. (2007) 6:56-65.
63. SILVER LL: A retrospective on the failures and successes of antibacterial drug discovery. IDrugsi (2005) 8(8):651-655.
64. FREIBERG C, BROTZ-OESTERHELT H: Functional genomics in antibacterial drug discovery. Drug Discov. Today (2005) 10(13):927-935.
65. KOEHL P, LEVITT M: A brighter future for protein structure prediction. Nat. Struct. Biol. (1999) 6(2):108-111.
66. JONES S, THORNTON JM: Searching for functional sites in protein structures. Curr. Opin. Chem. Biol. (2004) 8(1):3-7.
67. MARTI-RENOM MA, STUART AC, FISER A et al.: Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. (2000) 29:291-325.
68. KONFORTI B: PSI-Phase I and beyond. Nat. Struct. Mol. Biol. (2004) 11(3):201.
69. BERMAN HM, WESTBROOK JD: The impact of structural genomics on the protein data bank. Am. J. Pharmacogenomics (2004) 4(4):247-252.
70. CHANDONIA JM, BRENNER SE: The impact of structural genomics: expectations and outcomes. Science (2006) 311(5759):347-351.
71. LUNDSTROM K: Structural genomics on membrane proteins: mini review. Comb. Chem. High Throughput Screen. (2004) 7(5):431-439.
72. SCHMID MB: Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat. Rev. Microbiol. (2004) 2(9):739-746.
73. XIANG Z: Advances in homology protein structure modeling. Curr. Protein Pept. Sci. (2006) 7(3):217-227.
74. MOULT J, FIDELIS K, ROST B, HUBBARD T, TRAMONTANO A: Critical assessment of methods of protein structure prediction (CASP) - round 6. Proteins (2005) 61(Suppl. 7):3-7.
75. MOULT J: Rigorous performance evaluation in protein structure modeling and implications for computational biology. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2006) 361(1467):453-458.
76. HASHIMOTO M, ICHIMURA T, MIZOGUCHI H et al.: Cell size and nucleoid organization of engineered Escherichia coli cells with a reduced genome. Mol. Microbiol. (2005) 55(1):137-149.
77. GERDES SY, SCHOLLE MD, CAMPBELL JW et al.: Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J. Bacteriol. (2003) 185(19):5673-5684.
78. RILEY ML, SCHMIDT T, WAGNER C, MEWES HW, FRISHMAN D: The PEDANT genome database in 2005. Nucleic Acids Res. (2005) 33:D308-D310.
79. ZHANG R, OU H-Y, ZHANG C-T: DEG, a database of essential genes. Nucleic Acids Res. (2004) 32:D271-D272.
80. ZALACAIN M, BISWAS S, INGRAHAM KA et al.: A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol. Biotechnol. (2003) 6(2):109-126.
81. SHAPIRO L, HARRIS T: Finding function through structural genomics. Curr. Opin. Biotechnol. (2000) 11(1):31-35.
82. SHEPARD W, HAOUZ A, GRANA M et al.: The crystal structure of Rv0813c from Mycobacterium tuberculosis reveals a new family of fatty acid-binding protein-like proteins in bacteria. J. Bacteriol. (2007) 189(5):1899-1904.
83. DRAKER KA, BOEHR DD, ELOWE NH, NOGA TJ, WRIGHT GD: Functional annotation of putative aminoglycoside antibiotic modifying proteins in Mycobacterium tuberculosis H37Rv. J. Antibiot. (Tokyo) (2003) 56(2):135-142.
84. CARD GL, PETERSON NA, SMITH CA et al.: The crystal structure of Rv1347c, a putative antibiotic resistance protein from Mycobacterium tuberculosis, reveals a GCN5-related fold and suggests an alternative function in siderophore biosynthesis. J. Biol. Chem. (2005) 280(14):13978-13986.
85. ROBERTS A, LEE SY, MCCULLAGH E, SILVERSMITH RE, WEMMER DE: YbiV from Escherichia coli K12 is a HAD phosphatase. Proteins (2005) 58(4):790-801.
86. SHIN DH, LOU Y, JANCARIK J et al.: Crystal structure of YjeQ from Thermotoga maritima contains a circularly permuted GTPase domain. Proc. Natl. Acad. Sci. USA (2004) 101(36):13198-13203.
87. DAIGLE DM, ROSSI L, BERGHUIS AM et al.: YjeQ, an essential, conserved, uncharacterized protein from Escherichia coli, is an unusual GTPase with circularly permuted G-motifs and marked burst kinetics. Biochemistry (2002) 41(37):11109-11117.
88. ZAREMBINSKI TI, HUNG LW, MUELLER-DIECKMANN HJ et al.: Structure-based assignment of the biochemical function of a hypothetical protein: a rest case of structural genomics. Proc. Natl. Acad. Sci. USA (1998) 95(26):15189-15193.
89. HERMANN JC, GHANEM E, LI Y et al.: Predicting substrates by docking high-energy intermediates to enzyme structures. J. Am. Chem. Soc. (2006) 128(49):15882-15891.
90. Assume that the bacterium is a right rectangular cylinder of 2 μm in height and 0.5 μm in radius capped on each end by a hemisphere of radius 0.5 μm.
91. RUIZ N, KAHNE D, SILHAVY TJ: Advances in understanding bacterial outer-membrane biogenesis. Nat. Rev. Microbiol. (2006) 4:57-66.
92. WOUTERS J: Crystallography of membrane proteins. Mini Rev. Med. Chem. (2003) 3:439-448.
93. HAJDUK PJ, GREER J: A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Disc. (2007) 6:211-219.
94. BARKER J, COURTNEY S, HESTERKAMP T, ULLMANN D, WHITTAKER M: Fragment screening by biochemical assay. Expert Opin. Drug Discov. (2006) 1(3):225-236.
95. FIORINO M, JOHNSON S, WQONG TY et al.: Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA (2005) 102(27):9499-9504.
96. TSAO DHH, SUTHERLAND AG, JENNINGS LD et al.: Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg. Med. Chem. (2006) 14:7953-7961.
97. RUSH TSI, GRANT JA, MOSYAK L, NICHOLS A: A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. (2005) 48:1489-1495.
98. BOEHM H-J, BOEHRINGER M, BUR D et al.: Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3-D guided optimization. A promising alternative to random screening. J. Med. Chem. (2000) 43:2664-2674.
99. OBLAK M, GRDADOLNIK SG, KOTNIK M et al.: Biophysical characterization of an indolinone inhibitor in the ATP-binding site of DNA gyrase. Biochem. Biophys. Res. Commun. (2006) 349(4):1206-1213.